First NCFB patient dosed in Phase IIa study of RESP-X

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Infex invites you to Alderley Park's 10th Anniversary SciTech Extravaganza

Saturday 14 September, 10:00am - 3:00pm Come and join us in Glasshouse at…


Infex to present RESP-X Phase I data at ERS Congress

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Webinar on Infex's Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…


Infex Therapeutics logo

Infex to present webinar on lead Phase II respiratory drug RESP-X

RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…


RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Clinical candidate nominated for COV-X programme

COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…


Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Listen to the podcast here Infex CEO Peter Jackson discusses the state of…